Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08DFF
|
|||
| Former ID |
DIB016308
|
|||
| Drug Name |
AM-001
|
|||
| Synonyms |
AM-001 (topical); AM-001 (topical), DermAct
Click to Show/Hide
|
|||
| Indication | Actinic keratosis [ICD-11: EK90.0; ICD-10: L57.0; ICD-9: 702] | Phase 2 | [1] | |
| Dermatological disease [ICD-11: DA24.Y] | Phase 2 | [2] | ||
| Company |
DermAct Pharmaceutical Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 1 (FGFR1) | Target Info | Antagonist | [3] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Adherens junction | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Proteoglycans in cancer | ||||
| Prostate cancer | ||||
| Melanoma | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| FGF signaling pathway | ||||
| Pathway Interaction Database | Glypican 1 network | |||
| Syndecan-4-mediated signaling events | ||||
| N-cadherin signaling events | ||||
| FGF signaling pathway | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| MAPK Signaling Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Hair Follicle Development: Induction (Part 1 of 3) | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Signaling Pathways in Glioblastoma | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01938599) Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis. U.S. National Institutes of Health. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.